Updates are available Correction dated 2024-04-25
Click to view Correction: https://doi.org/10.1007/s40121-024-00947-w
-
Authors
Strizki, Julie M. http://orcid.org/0009-0002-3893-9374
Grobler, Jay A.
Murgolo, Nicholas
Fridman, Arthur
Johnson, Matthew G.
Du, Jiejun
Carmelitano, Patricia
Brown, Michelle L.
Paschke, Amanda
De Anda, Carisa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04575597 at ClinicalTrials.govDocuments that mention this clinical trial
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
https://doi.org/10.1007/s15010-022-01959-9
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
https://doi.org/10.1007/s40121-023-00891-1
-
Funding
Funding for this research was provided by:
Merck & Co, Inc.
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 31 October 2023
First Online: 23 November 2023
Change Date: 25 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-024-00947-w
Declarations
:
: Julie M. Strizki, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, and Carisa De Anda are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), who may own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Jiejun Du and Jay A. Grobler were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), at the time the study was conducted. Jiejun Du is currently an employee of Moderna, and Jay A. Grobler is currently an employee of Pfizer Inc.
: Our company’s approach to the conduct of clinical trials is in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and the applicable regulatory requirement(s). The trial was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards/ethics committees and regulatory agencies at all institutions/study sites (see Table S8). Written informed consent was provided by all participants prior to their enrollment into the trial. No identifying information for any trial participant is included in the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship on this publication, take responsibility for the integrity of the work as a whole, and have given their approval for this final version to be published.
